FDA Study Suggests Yaz and Other Drospirenone-Contaning Birth Control Pills More Likely to Cause Blood Clots

The U.S. Food and Drug Administration recently issued an updated safety communication regarding Bayer Pharmaceutical’s widely-used birth control pills, Yaz and Yasmin, citing that women using these drugs are 75 percent more likely to develop blood clots compared to those who use older-generation pills.

As a result of the FDA’s study, which followed 800,000 women between the years 2001 and 2007, researchers from the FDA, Kaiser Permanente, Vanderbilt University and the University of Washington ultimately found that drospirenone-containing birth control pills increased the risk of blood clots, otherwise known as venous thromboembolic events (VTE), by 75 percent over pills containing progestin levonorgestrel.

Additionally, the study’s findings backed several claims raised by thousands of women who have filed Yaz-related lawsuits, all of whom experienced serious blood clots as a result of using drospirenone-containing birth control pills like Yaz, Yasmin, Beyaz, Gianvi, Loryna, Safyral, Syeda Zarah and/or Ocella.

The FDA will present the new data at a December 8th meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>